𧬠Pharmacological Profile
Tirzepatide is a next-generation linear peptide engineered as a synthetic "twincretin"βa single molecule that functions as a dual agonist at both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. This structural integration yields synergistic downstream therapeutic effects far exceeding single-agonist capabilities.
The addition of GIP receptor activity alters the regulatory pathway entirely: while GLP-1 aggressively targets central appetite suppression in the hypothalamus and delays gastric emptying, GIP directly modifies metabolic performance within peripheral white adipose tissues. This enhances lipid buffering, improves insulin sensitivity, and counteracts the compensatory decrease in basic energy expenditure typically observed during severe caloric deficits.